Nurix Therapeutics (NRIX) Long-Term Investments (2019 - 2024)

Nurix Therapeutics (NRIX) has 6 years of Long-Term Investments data on file, last reported at $9.5 million in Q3 2024.

• Long-Term Investments for Q3 2024 came in at $9.5 million, down 4.15% year-over-year; the trailing twelve-month figure through Aug 2024 was $9.5 million (down 4.15% YoY), and the FY2023 annual result was $7.4 million, down 88.38% from the prior year.
• Long-Term Investments advanced to $9.5 million in Q3 2024 per NRIX's latest filing, from $9.4 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $137.2 million in Q4 2021 and troughed at $7.4 million in Q4 2023.
• A 5-year average of $59.3 million and a median of $51.5 million in 2022 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2020 and 2023: Long-Term Investments jumped 17862.45% in 2020, then slumped 88.38% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $90.9 million in 2020, then surged by 50.94% to $137.2 million in 2021, then plunged by 53.44% to $63.9 million in 2022, then tumbled by 88.38% to $7.4 million in 2023, then grew by 27.64% to $9.5 million in 2024.
• Business Quant data shows NRIX's Long-Term Investments at $9.5 million in Q3 2024, $9.4 million in Q2 2024, and $10.3 million in Q1 2024.